Amino Acid Sequence Disclosed In Whole Or In Part; Or Conjugate, Complex, Or Fusion Protein Or Fusion Polypeptide Including The Same Patents (Class 424/185.1)
  • Patent number: 11311598
    Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: April 26, 2022
    Assignee: Soligenix, Inc.
    Inventors: Oreola Donini, Annett Rozek, Jackson Lee, John North, Michael Abrams
  • Patent number: 11298404
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a WIC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: April 12, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 11291718
    Abstract: The present invention provides a medicine comprising a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: April 5, 2022
    Assignee: CYTLIMIC INC.
    Inventors: Tomoya Miyakawa, Shun Doi, Koji Tamada
  • Patent number: 11273200
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: March 15, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 11266708
    Abstract: The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble Fc?RIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: March 8, 2022
    Assignee: SUPPREMOL GMBH
    Inventors: Peter Sondermann, Thomas Pohl
  • Patent number: 11260010
    Abstract: The present invention relates to cochleates using phosphatidylserine/anionic surfactant/calcium chloride and, more specifically, to cochleates comprising phosphatidylserine, an anionic surfactant, calcium chloride, an active ingredient, and water.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: March 1, 2022
    Assignee: H&A PHARMACHEM CO., LTD
    Inventors: Hong Geun Ji, Hae In Choi, Young Ah Park, Yu Jin Kang
  • Patent number: 11254915
    Abstract: Provided is a method for separating and extracting mesenchymal stem cells from the human umbilical cord. The method uses healthy neonatal umbilical cord tissue; after cleaning and disinfection, mechanically pulverising same, separating the Wharton's jelly, and after treating with erythrocyte lysate, carrying out suspension culture in a serum-free culture medium. Replacing the liquid every 3-5 days; after the plate adherence rate reaches 30-70%, carrying out trypsin digestion, and then collecting the cells by centrifugation for passage amplification, until the rate of confluence of the cells reaches 80-90% confluence, thereby obtaining high purity umbilical cord mesenchymal stem cells.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 22, 2022
    Inventors: Lei Guo, Cheng Li
  • Patent number: 11246942
    Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 15, 2022
    Assignee: City of Hope
    Inventors: John C. Williams, David A. Horne, Yuelong Ma, Heng Wei Chang, Joshua Michael Donaldson, Cindy Zer, Krzysztof Bzymek, Kendra Nicole Avery, Jun Xie
  • Patent number: 11246943
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: February 15, 2022
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 11248213
    Abstract: Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: February 15, 2022
    Assignee: The Regents of the University of California
    Inventors: Richard Klemke, Huawei Wang
  • Patent number: 11246890
    Abstract: Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: February 15, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Tzuhua Dennis Lin, Stuart B. Goodman, Sai-Wen Tang, Everett Hurteau Meyer, Magdiel Pérez Cruz
  • Patent number: 11241482
    Abstract: The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: February 8, 2022
    Assignees: NOVARTIS AG, The Scripps Research Institute
    Inventors: Lori Jennings, Kristen Johnson, Peter Schultz
  • Patent number: 11191820
    Abstract: The present invention relates to a therapeutic peptide T specific immune therapy for use in the treatment of a cancer of an HLA-A2 (Human Leukocyte Antigen A2) positive patient, said treatment comprises a priming period consisting in two to three administrations of said therapeutic peptide T specific immune therapy, thereby inducing a memory T cell response.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: December 7, 2021
    Assignee: OSE Immunotherapeutics
    Inventor: Dominique Costantini
  • Patent number: 11186824
    Abstract: The present invention relates to methods for developing engineered immune cells such as T-cells for immunotherapy that have a higher potential of persistence and/or engraftment in host organism. IN particular, this method involves an inactivation of at least one gene involved in self/non self recognition, combined with a step of contact with at least one non-endogenous immunosuppressive polypeptide. The invention allows the possibility for a standard and affordable adoptive immunotherapy, whereby the risk of GvH is reduced.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: November 30, 2021
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Jean-Pierre Cabaniols, Julien Valton, Laurent Poirot
  • Patent number: 11160851
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: November 2, 2021
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • Patent number: 11154601
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen are disclosed. Methods of treating a subject with a BORIS-expressing tumor and methods of preventing a BORIS-expressing tumor are disclosed. A synthetic consensus BORIS antigen is disclosed.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: October 26, 2021
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
  • Patent number: 11129892
    Abstract: Described herein is a composition comprising: 1) an ARC polypeptide or an endogenous gag (endo-gag) polypeptide; 2) a pathogen-associated antigen; and 3) an adjuvant. Also described herein are vaccines and methods of vaccination using compositions comprising: 1) an ARC polypeptide or an endogenous gag (endo-gag) polypeptide; 2) a pathogen-associated antigen; and 3) an adjuvant.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: September 28, 2021
    Assignee: VNV NEWCO INC.
    Inventors: Zachary Gilbert, Colin Malone
  • Patent number: 11124799
    Abstract: Vaccines, methods of producing, and methods of using are provided in which a protective response to Valley Fever disease is produced when administered to an animal. The vaccine provides for expression of Coccidioides sp. Ag2 polypeptide in a plant or plant part, linked to a promoter preferentially directing expression to seed tissue of the plant or plant part. Further embodiments provide the polypeptide is targeted to the cell wall, vacuole or endoplasmic reticulum. The polypeptide may be fused to a dendritic cell targeting dendritic cell or a heat labile enterotoxin. Increased expression levels in the plant or plant part are obtained. The vaccine comprising the plant-produced Ag2 polypeptide may be a glucan chitin particle comprising the Ag2 polypeptide. The plant or plant materials in an embodiment may be orally administered.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: September 21, 2021
    Assignee: Applied Biotechnology Institute, Inc.
    Inventors: John Howard, Celine Hayden
  • Patent number: 11111284
    Abstract: The invention features homo-multimers, e.g., homo-trimers, of TNFSF or TNF-like ligand muteins in which each TNFSF ligand or TNF-like ligand mutein monomer contains at least one cysteine residue substitution or insertion that promotes the formation of a disulfide bond with a cysteine residue on a neighboring TNFSF or TNF-like ligand mutein monomer. The invention features methods of producing such TNFSF and TNF-like ligand muteins, pharmaceutical compositions containing such muteins, and methods of using such muteins in cancer immunotherapy, in treating autoimmune and neurological diseases, and in reducing or eliminating the complications and risks of rejection in organ transplantation or tissue or organ repair or regeneration.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: September 7, 2021
    Assignee: The General Hospital Corporation
    Inventors: Denise L. Faustman, Eva Vanamee
  • Patent number: 11103436
    Abstract: A peptide consisting of an amino acid sequence of SEQ ID NO: 1, 2, 3, or 4, a pharmaceutical composition for preventing or treating skin disease including the peptide, a cosmetic composition for skin condition improvement including the peptide, a food composition for skin condition improvement including the peptide, a method of preventing or treating skin disease using the peptide, and a use of the peptide in preventing or treating skin disease or improving skin condition are described.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: August 31, 2021
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung Ji Lee
  • Patent number: 11104712
    Abstract: The present disclosure provides methods of modulating an immune response in an individual. The present disclosure provides methods of treatment. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) and an immune checkpoint inhibitor to an individual. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) to an individual who is undergoing treatment with immune checkpoint inhibitor.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: August 31, 2021
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
  • Patent number: 11077171
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: August 3, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 11077177
    Abstract: Described herein are compositions of matter and methods for treating cancer. The compositions comprise altered human telomerase polypeptides containing T cell epitopes that have been altered to increase immunogenicity. The methods comprise administration of the polypeptides or nucleic acids, such as DNA or RNA encoding the polypeptides, to individuals afflicted with, or at risk of, developing cancer.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: August 3, 2021
    Inventor: Maurizio Zanetti
  • Patent number: 11065318
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 20, 2021
    Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang
  • Patent number: 11058720
    Abstract: The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: July 13, 2021
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Maya Koronyo, Altanchimeg Rentsendorj, Yosef Koronyo, Keith Black
  • Patent number: 11052134
    Abstract: Methods of treating an age-related disorder in a subject are provided. Aspects of the methods include administering to the subject a nucleic acid vector including a coding sequence for telomerase reverse transcriptase (TERT) and/or telomerase RNA (TR). Gene therapy methods are also provided. Aspects of the invention further include compositions, e.g., nucleic acid vectors and kits, etc., that find use in methods of the invention.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: July 6, 2021
    Assignee: Sierra Sciences, LLC
    Inventors: William H. Andrews, Lancer K. Brown, Hamid Mohammadpour, Laura A. Briggs
  • Patent number: 11053296
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: July 6, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Janet Peper, Kevin Roehle, Philipp Wagner, Hans-Georg Rammensee
  • Patent number: 11053545
    Abstract: The invention provides microRNA markers and methods for determining the risk a subject has for developing mild traumatic brain injuries (mTBI). In some aspects, the methods further include determine the fitness of a subject for participating in an activity with increased chances of receiving a head impact. Certain embodiments are directed to kits designed for these purposes.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: July 6, 2021
    Assignee: The Translational Genomics Research Institute
    Inventors: Kendall Van Keuren-Jensen, Matthew Huentelman, Ashish Yeri
  • Patent number: 11040093
    Abstract: A composition for treating type 1 diabetes mellitus autoimmunity can include a therapeutically effective amount of two or more overlapping fragments of preproinsulin and a pharmaceutically acceptable carrier, wherein at least one of the polypeptide fragments is antigenic.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: June 22, 2021
    Assignee: Phaim Pharma Ltd
    Inventors: Tihamer Orban, Jalahej Heyman, Nara Daubeney, Piers Daubeney
  • Patent number: 11033559
    Abstract: A lysophospholipid receptor-activating substance is able to normalize abnormal blood vessels in tumors without affecting normal blood vessels and to thus induce or promote infiltration of leukocytes into the whole or partial region of a tumor. Therefore, such a lysophospholipid receptor-activating substance is useful as a leukocyte infiltration promoter and an antitumor immunostimulant. Moreover, such a lysophospholipid receptor-activating substance can enhance cancer immunotherapy when used in combination with cancer immunotherapy, and is therefore useful as an agent for enhancing cancer immunotherapy.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: June 15, 2021
    Assignee: OSAKA UNIVERSITY
    Inventors: Nobuyuki Takakura, Hisamichi Naito, Kazuhiro Takara
  • Patent number: 11033564
    Abstract: Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: June 15, 2021
    Assignee: ImmunoGen, Inc.
    Inventors: Jose Ponte, Jan Pinkas, Rodrigo R. Ruiz-Soto
  • Patent number: 11034948
    Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: June 15, 2021
    Assignee: Codexis, Inc.
    Inventors: Scott J. Novick, Xiang Yi, Nikki Dellas, Oscar Alvizo, Jovana Nazor, Da Duan, Vesna Mitchell, Jonathan Vroom, Santhosh Sivaramakrishnan, Nandhitha Subramanian, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Grant Murphy, Nicholas M. Marshall, Jay Russell, Keith A. Canada
  • Patent number: 11013781
    Abstract: The invention relates to combinations of peptides derived from a portion of an amino sequence of a grass pollen allergen, e.g. the allergens Phl p 1, Phl p 2, Phl p 3, Phl p 4 and/or Phl p 5, or a peptide variant thereof. Such peptides comprise at least one T cell epitope mid a high number of patients in a worldwide population will have HLA Class II alleles with the potential to bind the peptides of the peptide combinations. The invention also relates to the use of such peptide combinations in relieving an immune response caused by grass pollen species.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: May 25, 2021
    Assignees: ALK-ABELLÓ AS, LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Claus Lundegaard, Shashank Gupta, Bjoern Peters, Susanne Sønderkær, Jens Brimnes, Peter Adler Würtzen, Helene Henmar, Thomas Christian Mygind, Lise Lund Mærkedahl, Alessandro Sette
  • Patent number: 11007166
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: May 18, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Mark Novas, Rui (Ray) Zhang
  • Patent number: 11000586
    Abstract: An adjuvant composition includes a pH-sensitive carrier and a substance with stimulus to activate innate immune system. The adjuvant composition serves as a carrier which is highly safe and capable of efficient induction of CTL.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: May 11, 2021
    Assignee: TERUMO KABUSHIKI KAISHA
    Inventor: Naoki Sakaguchi
  • Patent number: 10973893
    Abstract: The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, ?FITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of ?FITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: April 13, 2021
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Eduardo Davila, Koji Tamada
  • Patent number: 10967015
    Abstract: A method for treating a tumor by administering to a subject in need of such treatment an effective amount for treating the tumor of a Poxviridae decapping deficient mutant virus. Also disclosed are mutant Poxviridae and pharmaceutical formulations for use in the method.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: April 6, 2021
    Assignee: New York University
    Inventor: Ian J Mohr
  • Patent number: 10968269
    Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules containing one or more Borrelia derived peptides are disclosed. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the sample-mounted use of MHC complexes and MHC multimers. Also comprised by the invention is the field of therapy and vaccine, including therapeutic/vaccine methods and therapeutic/vaccine compositions.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: April 6, 2021
    Assignee: Agilent Technologies, Inc.
    Inventors: Jørgen Schøller, Liselotte Brix, Henrik Pedersen
  • Patent number: 10947297
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: March 16, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • Patent number: 10947278
    Abstract: Provided is a recombinant vector including a porcine Fc fragment. By fusing the porcine Fc fragment with various target proteins by using the recombinant vector of the present invention, not only target proteins may be expressed using various hosts including plants, but the productivity and stability of target proteins may also be increased.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: March 16, 2021
    Assignee: BIOAPPLICATIONS INC.
    Inventor: Yongjik Lee
  • Patent number: 10945962
    Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: March 16, 2021
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Joseph A. Vetro, Sam D. Sanderson
  • Patent number: 10933118
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: March 2, 2021
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 10927143
    Abstract: The invention relates to a process for decontaminating a biological material by partitioning and inactivation techniques. The process includes the formation of a three-layer liquid system (a-b-c), where the layers are placed one onto the other and are different from each other in density and/or miscibility properties. The upper layer (a) has an aqueous solution of the biological material to decontaminate; the lower layer (c) has the solution inactivating viruses, prions or bacteria; the intermediate layer (b), interposed between the upper and lower layers, separates and protects the biological material from the inactivating solution which has an organic solvent or a mixture of more such solvents, immiscible at least with the upper layer. Moreover, the invention provides specific indications about the density difference between the layers in order to preserve system stability and, at the same time, protect the efficiency of decontamination and the biological activity of the material undergoing decontamination.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: February 23, 2021
    Assignee: ALTERGON S.A.
    Inventors: Costantino Cozzari, Luca Angiolini
  • Patent number: 10925902
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: February 23, 2021
    Assignee: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Patent number: 10927161
    Abstract: The present disclosure provides methods of modulating an immune response in an individual. The present disclosure provides methods of treatment. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) and an immune checkpoint inhibitor to an individual. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) to an individual who is undergoing treatment with immune checkpoint inhibitor.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: February 23, 2021
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
  • Patent number: 10927188
    Abstract: Provided is a method for producing a short-chain peptide-immobilized carrier that maintains a secondary structure of a short-chain peptide, the method including a step of preparing an alcohol solution containing an alcohol solvent, and a short-chain peptide having a plurality of immobilizing functional groups, the short-chain peptide having a secondary structure induced in the alcohol solvent; and a step of bringing a carrier coupled with a spacer having a reactive group that reacts with the immobilizing functional group, into contact with the alcohol solution, and thereby immobilizing the short-chain peptide to the spacer.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: February 23, 2021
    Assignee: FUJIFILM Corporation
    Inventor: Koichi Minami
  • Patent number: 10905741
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 2, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 10898546
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: January 26, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 10889638
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 12, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Patent number: 10882894
    Abstract: The present invention provides peptidic TGF-? antagonists capable of inhibiting TGF-? signaling and disrupting the biochemical events that promote fibrosis and the epithelial-mesenchymal transition. The peptidic TGF-? antagonist may contain from 11 to 28 amino acid residues (for instance, may consist of from 12 to 16 amino acid residues) and may have the following structure (II): NH2? ETWIWLDTNMG-Xaa1-Y?COOH (II) wherein Xaa1 is any amino acid and Y is a peptide having from 0 to 9 amino acids. The peptidic TGF-? antagonists can advantageously be used for the prevention, treatment, and/or alleviation of the symptoms of a condition associated with an increase in TGF-? activity, including fibrosis (such as fibrosis of the skin, liver, lungs, and heart, among others) and cancer (including various carcinomas, such as squamous cell carcinoma, sarcomas, and metastatic cancers).
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: January 5, 2021
    Inventor: Anie Philip